Esperion stockholders approve merger agreement at special meeting

Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc.

ESPR

0.00
  • Esperion Therapeutics held a special stockholder meeting on July 8, 2026 to vote on a proposed merger agreement.
  • Stockholders adopted the merger agreement, clearing the way for Essence MergerCo to merge into Esperion, subject to closing conditions.
  • An advisory vote on merger-related executive compensation was also adopted.
  • A proposal to adjourn the meeting to solicit additional proxies was not put to a vote.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Esperion Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-081588), on July 08, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.